Marie-Françoise Mégie

YOUNG TRAINEES AND STUDENTS: Advocate for continued support of and investment in the next generation of highly skilled researchers through the federal awards system for doctoral students, post-doctoral trainees and fellows. RESEARCH HOSPITALS: Advocate for direct support and stability for Canada's academic health science centres and research hospitals that will further enable them to fulfill their strategically critical contribution to Canada's health and economic security. INDUSTRY: Advocate for policies that enhance the health and biosciences sector’s capacity to do business in Canada and to invest in Canadian health research and commercialization. INDIRECT COSTS OF RESEARCH: Advocate for an increase to the minimum threshold for reimbursement of indirect research costs for all institutions via the Research Support Fund. INDIGENOUS RESEARCH: Advocate for greater investments in Indigenous health research through the three granting councils and the Canada Research Coordinating Committee. HEALTH RESEARCH: Focus on increasing public investments across the research spectrum of operating grants, people and infrastructure and encourages investments from private and private-not-for-profit sectors. GOVERNMENT FUNDING: Advocate for increased health research funding through the three granting councils (Canadian Institutes of Health Research, Social Sciences and Humanities Research Council, and Natural Sciences and Engineering Research Council of Canada) and the Canada Research Coordinating Committee. FEDERAL BUDGET CONSULTATION: Advocate for continued support of Canadian health research and health innovation through investments and commitments made in the federal budget, such as the Strategic Science Fund, the Canada Graduate Scholarship Program, etc. DIVERSE TALENT BASE: Advocate for better support for a diversified talent base in Canada, with a focus on Indigenous researchers, Black and people of colour researchers, early-career researchers, and other underrepresented and equity-deserving groups. DIGITAL HEALTH SYSTEM: Advocate for investment in the digitalization of our health system so that high-quality data and digital technologies support healthcare decisions, empower patients as partners, and drive research and innovation.

INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector including input on Bill C-27, and the means through which advancements can be foreseen and managed. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to health care facilities for health care workers and patients. PERSONAL INFORMATION PROTECTION AND ELECTRONIC DOCUMENT ACT (PIPEDA) PRIVACY PROTECTION OF HEALTH INFORMATION AND THE REGULATORY REVIEW: Improvement to privacy legislation to protect the privacy of health information. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. NET ZERO: Advocate for sustainable health systems in Canada, including reaching net-zero emissions by 2050; advocate for the establishment of a national climate and health secretariat within the federal government to develop a pan-Canadian approach to addressing the impacts of climate change and health; and advocate for a targeted health infrastructure fund as part of the federal government’s long-term plan for public infrastructure. MEDICAL ASSISTANCE IN DYING: Advancing the medical profession’s perspectives on medical assistance in dying. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. INDIGENOUS HEALTH AND RECONCILIATION WITH INDIGENOUS PEOPLES: Implementation of the Calls to Action of the Truth and Reconciliation Commission, including addressing the ongoing structural inequities that marginalize Indigenous Peoples, advancing the inclusion of Indigenous Peoples in societal systems and sectors, including health systems, and committing to collaborative and respectful relationships with Indigenous patients and communities. The CMA is also advocating to increase trust between Ind

The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs Improve safeguards for Canadian health data Improve labour mobility so physicians can work across the country Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. THE ACQUISITION AND THE DOMESTIC SUPPLY OF PERSONAL PROTECTIVE EQUIPMENT FOR HEALTH CARE PROVIDERS: Ensuring the federal government take additional measures ensure adequate supply, proper distribution, and appropriate usage of personal protective equipment throughout health systems. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector including input on Bill C-27, and the means through which advancements can be foreseen and managed. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to

TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs Improve safeguards for Canadian health data Improve labour mobility so physicians can work across the country Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES: Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Cauc

Bill S-201, National Framework on Sickle Cell Disease Act, respecting provisions outlined in Section 2, subsections (a), (b), (e), and (i). Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada. Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases. Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Implementation of Canada's action plan for pain and federal initiatives related to pain management. Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Urging Immigration, Refugees and Citizenship Canada, in collaboration with Health Canada, to reconsider introducing copayments for medications and supplemental health services under the Interim Federal Health Program (IFHP) for refugees and asylum seekers. Pandemic Planning: ensure all nurses are properly supported and protected by maintaining appropriate stockpiles of personal protective equipment (PPE), providing mental health supports for those working on the front lines, and ensuring nursing students receive adequate assistance. Increase access to education and training for nurses returning to work or working across various care settings during public health emergencies. Ensure clear guidelines and resources are developed and disseminated, and that senior nurses are included in discussions and advisory boards during emergency planning phases as well as in post-emergency reviews. Discussions aim to ensure that artificial intelligence and emerging health technologies are developed, assessed, and approved in ways that meet the needs of the Canadian population. Communications emphasize the importance of integrating nursing perspectives into governance, regulation, clinical and ethical evaluation, and approval processes for new technologies. Communications relate to ongoing efforts to strengthen the collection, harmonization, and use of nursing workforce data at the pan-Canadian level. Discussions include modelling future health and workforce needs, supporting evidence-based health human resource planning, and investing in robust data systems to inform public policy and decision-making. Discussions include a request for federal funding to support the organization of CNA's 2026 national conference, which will bring together nursing leaders, health system partners, and policy-makers to advance dialogue on workforce priorities, innovation, public health, and health system transformation. Communications address the need for federal investment in strategies to improve retention of nursing professionals, including support for mental health and well-being, improved working conditions, continuing professional development, and initiatives to reduce burnout and strengthen workforce stability across all regions of Canada. Discussions focus on measures to expand the capacity to educate and support Indigenous nurses across Canada, including targeted investments in nursing education programs, partnerships with Indigenous and community-based institutions, and initiatives that improve access, retention, and graduation outcomes for Indigenous nursing students. Support the development of a national licensure framework for nurses. Enhance nursing leadership at the federal level and ensure ongoing support, resources, and sustainability for Chief Nursing Officer roles in all provinces and territories. Communications relate to federal measures aimed at protecting health-care workers, including initiatives to improve workplace safety, prevent harassment and violence, and strengthen legislative and regulatory frameworks that support a safe and respectful environment for health professionals. Bill S-233, An Act to amend the Criminal Code (assault against persons who provide health services and first responders) Harmonize nursing regulatory practices to support a responsive and sustainable nursing workforce Support a Canadian Nurse Practitioner Initiative based on past similar initiatives Allow nurses to certify the Disability Tax Credit form Seek funding for nursing research, including Indigenous nursing Create a pan-Canadian health human resources strategy Urging the federal government to lead the development of and work with the provinces and territories to implement a pan-Canadian digital health strategy. That the federal government lead efforts to educate health-care workers on the importance of medication safety and deprescribing Support for regulated nurses working at full scope of practice Strengthening of programs and supports for vulnerable po

Urging the federal government to lead the development of and work with the provinces and territories to implement a pan-Canadian digital health strategy. That the minister of health create a public awareness campaign to bring attention to the scourge of counterfeit prescription drugs That the federal government lead efforts to educate health-care workers on the importance of medication safety and deprescribing Support for regulated nurses working at full scope of practice Strengthening of programs and supports for vulnerable populations, including child health, senior's health and domestic maternal, newborn and child health strategy development. Strengthening and creating programs to support illness prevention and health promotion, long term care, palliative care, home and community care, affordable housing and other social determinants of health Strategies to address the health human resources crisis and nursing shortages across Canada, including providing funding to provinces and territories to help optimize workloads; financial supports for nurses and health-care workers such as loan forgiveness, tax incentives, retention bonuses for senior nurses; creating a mental health action plan for health-care workers; increasing training and education for health-care workers. Seeking funding for the Nursing the Future initiative Seek funding for nursing research Review the Income Tax Act, List of Authorized Medical Practitioners to ensure all categories of nurses are easily identified. Requesting the federal government to create a one-time fund of $1.2 billion over four years via the Primary Care Transition Fund II to expand the establishment of primary care teams in each province and territory, with a special focus in remote and underserved communities. Reinstate the position of a Chief Nursing Officer at the federal level, and support for CNO's in all provinces and territories. Provide funding for a comprehensive, universal, public, affordable prescription medication coverage that ensures access in all health-care settings based on need and not the ability to pay Protection of public from the ongoing and growing threat of antimicrobial resistance Pandemic Planning and COVID-19: ensure all nurses are properly supported and protecting by ensuring appropriate stockpiling of PPE, support for mental health while on the front lines, support for nursing students, increased access to education and training when return to work or working in various care setting while responding to a pandemic, ensuring appropriate guidelines and resources are disseminated and developed and ensure senior nurses are part of discussions and advisory review boards during pandemics in planning phases as well as post pandemic in the review. Nursing-entry to practice Invest in strategies to prevent and mitigate the health effects of climate change Influencing the Canada Health Transfer and Health Bilateral Agreements between the federal government and provinces and territories to urge governments to increase healthcare investments and invest in priority areas such as the health workforce, primary care, long-term care, mental health, data and virtual care, and surgeries and backlogs. Increasing federal health transfers to the provinces and territories via a demographic top-up to meet the needs of Canada's aging population. Increase support to Canadians who provide care for aging relatives and friends. Incorporate Primary Health Care (PHP) principles within a Health in All Policies approach Improving care in long-term care facilities through enhanced access to and provision of care from regulated nurses. Improve community- and home-based health promotion Improve access to primary care, home care, and palliative and end-of-life care for all people in Canada. Funding to support nursing certification across Canada to strengthen the safe delivery of expert care to older adults. Funding to support newly graduated nurses moving into professional practice for the first tim

Clean electricity regulations and emissions cap Investing in Employment Insurance, care workers, unionized jobs and strong workplace standards Addressing the high cost of living and investing in affordable housing Implementation of universal pharmacare, dental care, long term care and mental health care Labour provisions in the Canada-Ecuador Trade Agreement and Canada-United States-Mexico Agreement. The regularization of undocumented workers, update and possible next steps for the CLC Out-of-status Construction Workers in the GTA project Bill C-65, Canada Elections Act With interest in provisions that impact Third Parties and contributions to Third Parties Bill C-27, Digitial Charter Implementation Act - Part III of C-27 and the impact of artificial intelligence on jobs and workers.

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Federal policies that relate to possible models of pharmacare Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations National Strategy for Drugs for Rare Diseases World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry World Health Organization (WHO) issues concerning the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Income Tax Act as it relates to biopharmaceutical products Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade agreements as they relate to the biopharmaceutical industry Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) The government's Science and Technology strategy as it relates to the biopharmaceutical industry Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations Smart Regulations as it relates to the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Proposed pharmacare legislation related to any future national pharmacare program Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products New Substances Notification Regulations as it relates to the biopharmaceutical industry Income Tax Act as it relates to biopharmaceutical products Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19 Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products Canada's Access to Medicines Regime with respect to ensuring that the program allows for the deli

Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments. The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada. Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally. Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic. Public policy issues related to Health Canada's review of NCE Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry. Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada. Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices. National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians. Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process. Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage. Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Discuss increasing incidents of violence against health care workers, prevention, and enforcement of existing laws. Support nursing students through targeted financial support such as paid preceptorships and federal grants. Support internationally educated nurses through establishing a collaborative, multi-stakeholder body hosted by Health Canada, to lead national strategy, planning and coordination for internationally educated nurses' registration, integration and support. Targeted funding of $1 billion as an initial investment to immediately begin to address the current health care workforce crisis experienced by provinces/territories across Canada, with funding focused on short and long-term goals. To achieve patient-centred quality care based on the WHO’s comprehensive health labour markets framework that would be acceptable to, and delivered by, the provinces/territories. Provide sustainable funding so nurses and other healthcare workers have access to mental health supports. In keeping with the recommendations of the Truth and Reconciliation Commission, establish specific targets and timelines for the admission and graduation of First Nations, Métis and Inuit health professionals in all postsecondary institutions and provide funding dedicated to indigenous nurse students. Implementing a Universal single-payer pharmacare program. Fund innovative retention and recruitment programs targeted at early-career, mid-career and late-career nurses. Establish a dedicated coordinating body to address critical health workforce data gaps based on global best practices on health workforce management. Address health workforce shortages through the implementation of a comprehensive, pan-Canadian health human resources strategy, in coordination with the provinces and territories, backed by sufficient funding and with real accountability for achieving desired health outcomes; and address critical data gaps through significantly enhancing existing health workforce data infrastructure to standardize data collection and analysis across workers, sectors and jurisdictions, with links to relevant patient information, healthcare utilization and outcome data, for more fit-for-purpose planning and tools available at the provincial, territorial, regional and training program level. In designing this, Canada should draw on global best practices in health workforce planning including in Australia and New Zealand.

The CHC supports the establishment of a national pharamcare program, based on the recommendations contained in the Final Report of the Advisory Council on the Implementation of National Pharmacare (2019). The CHC supports the establishment of national standards for long term care, supported through conditional federal financial funding. The CHC supports the Canada Health Act and the enforcement of its provisions by the federal government using its spending authority. The CHC support Canada's voluntary-collection system for blood and blood products, including plasma. It opposes the paid-collection of blood and blood products.

Increase support and funding on issues related to global migration and forced displacement, including on operational responses to new arrivals in Canada. Engage in governmental dialogue on issues related to international humanitarian law (IHL), with specific reference to ensuring the protection of populations experiencing increased vulnerabilities and the delivery of humanitarian assistance during times of armed conflict. Build support and obtain grant funding for community service organizations in Canada. Build support for health and public initiatives, including but not limited to supports targeted to mental health and seniors. Increase support and investment in diverse programming for indigenous communities, including preparedness, risk reduction, emergency response and recovery. Secure investments in readiness for all-hazard response, including health emergencies and public health crises in Canada and around the world.